z-logo
Premium
Paladin is a phosphoinositide phosphatase regulating endosomal VEGFR2 signalling and angiogenesis
Author(s) -
Nitzsche Anja,
Pietilä Riikka,
Love Dominic T,
Testini Chiara,
Ninchoji Takeshi,
Smith Ross O,
Ekvärn Elisabet,
Larsson Jimmy,
Roche Francis P,
Egaña Isabel,
Jauhiainen Suvi,
Berger Philipp,
ClaessonWelsh Lena,
Hellström Mats
Publication year - 2020
Publication title -
embo reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.584
H-Index - 184
eISSN - 1469-3178
pISSN - 1469-221X
DOI - 10.15252/embr.202050218
Subject(s) - angiogenesis , signalling , endosome , microbiology and biotechnology , phosphatase , vegf receptors , biology , cancer research , phosphorylation , intracellular
Cell signalling governs cellular behaviour and is therefore subject to tight spatiotemporal regulation. Signalling output is modulated by specialized cell membranes and vesicles which contain unique combinations of lipids and proteins. The phosphatidylinositol 4,5‐bisphosphate (PI(4,5)P 2 ), an important component of the plasma membrane as well as other subcellular membranes, is involved in multiple processes, including signalling. However, which enzymes control the turnover of non‐plasma membrane PI(4,5)P 2 , and their impact on cell signalling and function at the organismal level are unknown. Here, we identify Paladin as a vascular PI(4,5)P 2 phosphatase regulating VEGFR2 endosomal signalling and angiogenesis. Paladin is localized to endosomal and Golgi compartments and interacts with vascular endothelial growth factor receptor 2 (VEGFR2) in vitro and in vivo . Loss of Paladin results in increased internalization of VEGFR2, over‐activation of extracellular regulated kinase 1/2, and hypersprouting of endothelial cells in the developing retina of mice. These findings suggest that inhibition of Paladin, or other endosomal PI(4,5)P 2 phosphatases, could be exploited to modulate VEGFR2 signalling and angiogenesis, when direct and full inhibition of the receptor is undesirable.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here